SSG
BIIB icon

Summit Securities Group’s Biogen BIIB Stock Holding History

Summit Securities Group’s Portfolio BIIB Stock Details BIIB Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q4 		– Sell
-500
Closed -$97K – 649
2024
Q3 		$97K Buy
+500
New +$105K 0.03% 187
2024
Q2 		– Sell
-800
Closed -$173K – 586
2024
Q1 		$173K Buy
+800
New +$187K 0.03% 165
2020
Q3 		– Sell
-30
Closed -$803K – 371
2020
Q2 		$803K Buy
+30
New +$9.02K 0.1% 173
2020
Q1 		– Sell
-10
Closed -$297K – 309
2019
Q4 		$297K Buy
+10
New +$2.77K 0.02% 353

Other funds holding BIIB

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Primecap Management
Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Summit Securities Group's BIIB Position: Q1 2026 in Review

Summit Securities Group reduced its Biogen (BIIB) stake by 89% in Q1 2026, selling an estimated $35.9K and leaving 24 shares worth $4.4K. The position accounts for ﹤0.01% of the portfolio, ranked #822.

Summit Securities Group first reported a position in BIIB in Q1 2016 and has held it in 14 quarters since. The position peaked at $1.71M in Q1 2016. 1,003 funds tracked by Wall St. Rank hold BIIB as of Q1 2026.

  • Summit Securities Group held 24 shares of Biogen worth $4.4K as of Q1 2026.
  • Summit Securities Group sold 195 Biogen shares in Q1 2026, an estimated $35.9K.
  • Biogen made up ﹤0.01% of Summit Securities Group's portfolio in Q1 2026, its #822 holding.
  • Summit Securities Group first reported a position in Biogen in Q1 2016 and has held it in 14 quarters since.
  • Summit Securities Group's Biogen position peaked at $1.71M in Q1 2016.
  • 1,003 funds tracked by Wall St. Rank held Biogen as of Q1 2026.

Based on Summit Securities Group's 13F filing for Q1 2026, filed 30 Apr 2026.